Effect of erythropoietin, 5-fluorouracil and SN-38 on the growth of DLD-1 cells

Pharmacological Reports

Volumn 62, Issue 5, 2010, Pages 926-937

  Tankiewicz Kwedlo, Anna ^a   Pawlak, Dariusz ^a   Domaniewski, Tomasz ^a   Buczko, Włodzimierz ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

5 Fluorouracil; Colon cancer cells; Erythropoietin; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ERYTHROPOIETIN RECEPTOR; FLUOROURACIL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL COUNT; CELL PROLIFERATION; CELL VIABILITY; COLON ADENOCARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOMETRY; DNA SYNTHESIS INHIBITION; DRUG POTENTIATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 79551480478     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70353-4     Document Type: Article

References (40)

1. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A: Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res, 2001, 61, 3561-3565.
2. Andreucci M, Fuiano G, Presta P, Lucisano G, Leone F, Fuiano L, Bisesti V et al.: Downregulation of cell survival signalling pathways and increased cell damage in hydrogen peroxide-treated human renal proximal tubular cells by alpha-erythropoietin. Cell Prolif, 2009, 42, 554-561.
3. Arcasoy MO, Amin K, Karayal AF, Chou SC, Raleigh JA, Varia MA, Haroon ZA: Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest, 2002, 82, 911-918.
4. Azrak RG, Cao S, Slocum HK, Tóth K, Durrani FA, Yin MB, Pendyala L et al.: Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res, 2004, 10, 1121-1129.
5. Berdel WE, Danhauser-Riedl S, Oberberg D, Zafferani M: Effects of hematopoietic growth factors on malignant nonhematopoietic cells. Semin Oncol, 1992, 19, 41-45.
6. Berdel WE, Oberberg D, Reufi B, Thiel E: Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. Ann Hematol, 1991, 63, 5-8.
7. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM et al.: Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA, 2000, 97, 10526-10531.
8. Buemi M, Allegra A, Corica F, Floccari F, D'Avella D, Aloisi C, Calapai G et al.: Intravenous recombinant erythropoietin does not lead to an increase in cerebrospinal fluid erythropoietin concentration. Nephrol Dial Transplant, 2000, 15, 422-423. (Pubitemid 30116482)
9. Celik M, Gökmen N, Erbayraktar S, Akhisaroglu M, Konakc S, Ulukus C, Genc S et al.: Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA, 2002, 99, 2258-2263.
10. Cho KH, Choi SM, Kim BC, Lee SH, Park MS, Kim MK, Kim JK: 5-Fluorouracil-induced oligodendrocyte death and inhibitory effect of cycloheximide, Trolox, and Z-VAD-FMK in murine cortical culture. Cancer, 2004, 100, 1484-1490.
11. Chong ZZ, Kang JQ, Maiese K: Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br J Pharmacol, 2003, 138, 1107-1118.
12. Durak I, Karaayvaz M, Kavutcu M, Cimen MY, Kaçmaz M, Büyükkoçak S, Oztürk HS: Reduced antioxidant defense capacity in myocardial tissue from guinea pigs treated with 5-fluorouracil. J Toxicol Environ Health A, 2000, 59, 585-589.
13. Fanciullino R, Giacometti S, Mercier C, Aubert C, Blanquicett C, Piccerelle P, Ciccolini J: In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation. Br J Cancer, 2007, 97, 919-926.
14. Grimm C, Wenzel A, Stanescu D, Samardzija M, Hotop S, Groszer M, Naash M et al.: Constitutive overexpression of human erythropoietin protects the mouse retina against induced but not inherited retinal degeneration. J Neurosci, 2004, 24, 5651-5658.
15. Hammerling U, Kroon R, Wilhelmsen T, Sjödin L: In vitro bioassay for human erythropoietin based on proliferative stimulation of an erythroid cell line and analysis of carbohydrate-dependent microheterogeneity. J Pharm Biomed Anal, 1996, 14, 1455-1469.
16. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW: Erythropoietin biology in cancer. Clin Cancer Res, 2006, 12, 332-339.
17. Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, Mose S et al.: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet, 2003, 362, 1255-1260. (Pubitemid 37324251)
18. Inoue Y, Miki C, Watanabe H, Hiro J, Toiyama Y, Ojima E, Yanagi H et al.: Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line. J Gastroenterol, 2006, 41, 1149-1157. (Pubitemid 46487205)
19. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ: The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol, 2008, 67, 39-61.
20. Khuri FR: Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med, 2007, 356, 2445-2448.
21. Kokura S, Yoshida N, Sakamoto N, Ishikawa T, Takagi T, Higashihara H, Nakabe N et al.: The radical scavenger edaravone enhances the anti-tumor effects of CPT-11 in murine colon cancer by increasing apoptosis via inhibition of NF-κB. Cancer Lett, 2005, 229, 223-233.
22. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A et al.: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol, 2005, 23, 5960-5972.
23. Mannello F, Tonti GA: Erythropoietin and its receptor in breast cancer: putting together the pieces of the puzzle. Oncologist, 2008, 13, 761-768.
24. Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM et al.: Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg, 2009, 249, 420-425.
25. Mihov D, Vogel J, Gassmann M, Bogdanova A: Erythropoietin activates nitric oxide synthase in murine erythrocytes. Am J Physiol Cell Physiol, 2009, 297, C378-388.
26. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 1983, 65, 55-63.
27. Okazaki T, Ebihara S, Asada M, Yamanda S, Niu K, Arai H: Erythropoietin promotes the growth of tumors lacking its receptor and a decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia, 2008, 10, 932-939.
28. Park HJ, Carr JR, Wang Z, Nogueira V, Hay N, Tyner AL, Lau LF et al.: FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J, 2009, 28, 2908-2918.
29. Paschos N, Lykissas MG, Beris AE: The role of erythropoietin as an inhibitor of tissue ischemia. Int J Biol Sci, 2008, 4, 161-168. (Pubitemid 351872045)
30. Prosnitz RG, Patwardhan MB, Samsa GP, Mantyh CR, Fisher DA, McCrory DC, Cline KE et al.: Quality measures for the use of adjuvant chemotherapy and radiation therapy in patients with colorectal cancer: a systematic review. Cancer, 2006, 107, 2352-2360.
31. Ravi R, Jain AJ, Schulick RD, Pham V, Prouser TS, Allen H, Mayer EG et al.: Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res, 2004, 64, 9105-9114.
32. Ray-Coquard I, Dussart S, Goillot C, Mayeur D, Debourdeau P, Ghesquieres H, Bachelot T et al.: A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin α: a prospective randomized controlled trial of the ELYPSE study group. Ann Oncol, 2009, 20, 1105-1112.
33. Sautina L, Sautin Y, Beem E, Zhou Z, Schuler A, Brennan J, Zharikov SI et al.:Induction of nitric oxide by erythropoietin is mediated by the β common receptor and requires interaction with VEGF receptor 2. Blood, 2010, 115, 896-905.
34. Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ, Han DC, Kwon BM: Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res, 2009, 69, 193-202.
35. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG: Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer, 2007, 110, 477-488.
36. Solár P, Koval J, Mikes J, Kleban J, Solárová Z, Lazúr J, Hodorová I et al.: Erythropoietin inhibits apoptosis induced by photodynamic therapy in ovarian cancer cells. Mol Cancer Ther, 2008, 7, 2263-2271.
37. Thews O, Kelleher DK, Vaupel P: Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res, 2001, 61, 1358-1361.
38. Tong H, Ren Y, Zhang F, Jin J: Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells. Eur J Haematol, 2008, 81, 259-266.
39. Tóvári J, Gilly R, Rásó E, Paku S, Bereczky B, Varga N, Vágó A et al.: Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models. Cancer Res, 2005, 65, 7186-7193.
40. Tsuboi M, Ezaki K, Tobinai K, Ohashi Y, Saijo N: Weekly administration of epoetin β for chemotherapy-induced aemia in cancer patients: Results of a multicenter, phase III, randomized, double-blind, placebo-controlled study. Jpn J Clin Oncol, 2009, 39, 163-168.